Validation of GATE 6.1 for targeted radiotherapy of metastic melanoma using 131I-labeled benzamide - Archive ouverte HAL Access content directly
Conference Papers Year : 2012

Validation of GATE 6.1 for targeted radiotherapy of metastic melanoma using 131I-labeled benzamide

(1) , (1) , (1) , (2)
1
2

Abstract

The GATE 6.1 Monte Carlo simulation platform based on the GEANT4 toolkit is in constant improvement for dosimetric calculations. Here, we explore its use for calculating internal absorbed dose distribution in mice for the treatment of malignant melanoma after injection of a new specific radiopharmaceutical labeled with iodine 131. We estimate the dosimetric accuracy of GATE 6.1, by calculating first S values and by comparing them and absorbed doses to organswith EGSnrc for a digital mouse phantom and a CT scan based mouse phantom.
Fichier principal
Vignette du fichier
Perrot_MCTP2012.pdf (232.25 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

in2p3-00703187 , version 1 (01-06-2012)

Identifiers

  • HAL Id : in2p3-00703187 , version 1

Cite

Y. Perrot, L. Maigne, Vincent Breton, D. Donnarieix. Validation of GATE 6.1 for targeted radiotherapy of metastic melanoma using 131I-labeled benzamide. Third European Workshop on Monte Carlo Treatment Planning, May 2012, Seville, Spain. 5 p. ⟨in2p3-00703187⟩
77 View
128 Download

Share

Gmail Facebook Twitter LinkedIn More